The Effect of a Life-Style Intervention Program of Diet and Exercise on Irisin and FGF-21 Concentrations in Children and Adolescents with Overweight and Obesity.

Szczegóły
Abstrakt

Tytuł:: The Effect of a Life-Style Intervention Program of Diet and Exercise on Irisin and FGF-21 Concentrations in Children and Adolescents with Overweight and Obesity.
Autorzy:: Karampatsou SI; Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527 Athens, Greece.
Genitsaridi SM; Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527 Athens, Greece.
Michos A; Division of Infectious Diseases, First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527 Athens, Greece.
Kourkouni E; Center for Clinical Epidemiology and Outcomes Research (CLEO), 11528 Athens, Greece.
Kourlaba G; Center for Clinical Epidemiology and Outcomes Research (CLEO), 11528 Athens, Greece.
Kassari P; Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527 Athens, Greece.
Manios Y; Department of Nutrition and Dietetics, Harokopio University of Athens, Kallithea, 17671 Athens, Greece.
Charmandari E; Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, 11527 Athens, Greece.; Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
Źródło:: Nutrients [Nutrients] 2021 Apr 13; Vol. 13 (4). Date of Electronic Publication: 2021 Apr 13.
Typ publikacji:: Journal Article; Observational Study
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI Publishing
MeSH Terms:: Healthy Lifestyle*
Fibroblast Growth Factors/*blood
Fibronectins/*blood
Overweight/*diagnosis
Pediatric Obesity/*diagnosis
Adolescent ; Biomarkers/blood ; Body Mass Index ; Cardiometabolic Risk Factors ; Child ; Child, Preschool ; Combined Modality Therapy/methods ; Exercise Therapy ; Feeding Behavior ; Female ; Follow-Up Studies ; Humans ; Male ; Overweight/blood ; Overweight/complications ; Overweight/therapy ; Pediatric Obesity/blood ; Pediatric Obesity/complications ; Pediatric Obesity/therapy ; Risk Assessment/methods ; Treatment Outcome ; Weight Loss
References:: Diab Vasc Dis Res. 2018 May;15(3):263-269. (PMID: 29424246)
Int J Obes (Lond). 2006 Dec;30(12):1775-81. (PMID: 16607382)
J Clin Endocrinol Metab. 2015 Apr;100(4):1289-99. (PMID: 25625801)
J Clin Endocrinol Metab. 2015 May;100(5):2123-30. (PMID: 25781361)
Diabetes. 2014 Dec;63(12):4057-63. (PMID: 25008183)
Acta Diabetol. 2014 Oct;51(5):705-13. (PMID: 24619655)
J Diabetes Complications. 2016 Nov - Dec;30(8):1560-1565. (PMID: 27539885)
J Clin Res Pediatr Endocrinol. 2017 Jun 1;9(2):124-131. (PMID: 28077341)
Nutr Metab Cardiovasc Dis. 2018 Jul;28(7):756-764. (PMID: 29858156)
Front Endocrinol (Lausanne). 2014 Jul 07;5:107. (PMID: 25071723)
Trends Pharmacol Sci. 2015 Jul;36(7):461-70. (PMID: 26022934)
Obesity (Silver Spring). 2015 Apr;23(4):729-32. (PMID: 25820255)
Nature. 2012 Jan 11;481(7382):463-8. (PMID: 22237023)
Front Med. 2019 Oct;13(5):511-530. (PMID: 31495905)
J Clin Endocrinol Metab. 2012 Jun;97(6):2143-50. (PMID: 22438225)
Obes Facts. 2019;12(1):25-39. (PMID: 30673672)
Cytokine. 2017 Jun;94:8-13. (PMID: 28385328)
J Clin Med. 2020 Feb 06;9(2):. (PMID: 32041319)
J Clin Endocrinol Metab. 2012 Jul;97(7):E1224-8. (PMID: 22539584)
Front Endocrinol (Lausanne). 2015 Sep 23;6:147. (PMID: 26441837)
J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907. (PMID: 24057291)
J Clin Res Pediatr Endocrinol. 2014 Sep;6(3):129-43. (PMID: 25241606)
J Am Diet Assoc. 2004 Apr;104(4):595-603. (PMID: 15054345)
Clin Endocrinol (Oxf). 2014 Dec;81(6):862-70. (PMID: 24841294)
Nutrients. 2015 Nov 13;7(11):9453-74. (PMID: 26580649)
Nat Rev Endocrinol. 2017 Jun;13(6):324-337. (PMID: 28211512)
Int J Endocrinol. 2014;2014:857270. (PMID: 24864142)
Cell Metab. 2013 Sep 3;18(3):333-40. (PMID: 24011069)
J Obes Metab Syndr. 2017 Sep;26(3):204-209. (PMID: 31089518)
Biomed Res Int. 2017;2017:2628968. (PMID: 28553647)
J Clin Endocrinol Metab. 2015 Aug;100(8):3004-10. (PMID: 26052728)
J Clin Densitom. 2019 Apr - Jun;22(2):179-184. (PMID: 30228048)
Nutr Metab (Lond). 2015 Sep 15;12:31. (PMID: 26379757)
Pediatr Obes. 2016 Aug;11(4):299-305. (PMID: 26305484)
BMJ Open. 2019 Aug 30;9(8):e028231. (PMID: 31473614)
PLoS One. 2013 Apr 22;8(4):e61432. (PMID: 23630589)
Obes Rev. 2017 Jun;18(6):603-634. (PMID: 28346723)
J Pediatr Endocrinol Metab. 2019 Sep 25;32(9):921-928. (PMID: 31323006)
Mol Neurobiol. 2018 Jun;55(6):4702-4717. (PMID: 28712011)
J Endocr Soc. 2019 Feb 15;3(4):825-837. (PMID: 30963140)
Sci Rep. 2015 May 18;5:10275. (PMID: 25985218)
Cell Metab. 2012 Sep 5;16(3):387-93. (PMID: 22958921)
J Clin Transl Endocrinol. 2015 Jun 1;2(2):77-82. (PMID: 26042208)
Lancet. 2017 Dec 16;390(10113):2627-2642. (PMID: 29029897)
Obesity (Silver Spring). 2014 Jul;22(7):1701-8. (PMID: 24644099)
PLoS One. 2014 Jun 13;9(6):e100218. (PMID: 24926783)
Obes Facts. 2019;12(2):244-258. (PMID: 31030201)
Biochim Biophys Acta. 2000 Jun 21;1492(1):203-6. (PMID: 10858549)
J Obes. 2018 Sep 12;2018:7461903. (PMID: 30298107)
PLoS One. 2013 Apr 11;8(4):e60563. (PMID: 23593248)
Pediatr Obes. 2012 Aug;7(4):284-94. (PMID: 22715120)
Genes Dev. 2012 Feb 1;26(3):271-81. (PMID: 22302939)
Horm Res Paediatr. 2020;93(2):94-107. (PMID: 32580197)
Grant Information:: (project code: T1EDK-01386, MIS: 5030543, Acronym: PEDOBESITY) This research has been co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE
Contributed Indexing:: Keywords: FGF-21; adolescence; childhood; irisin; obesity; overweight
Substance Nomenclature:: 0 (Biomarkers)
0 (FGF21 protein, human)
0 (FNDC5 protein, human)
0 (Fibronectins)
62031-54-3 (Fibroblast Growth Factors)
Entry Date(s):: Date Created: 20210430 Date Completed: 20210607 Latest Revision: 20231101
Update Code:: 20240104
PubMed Central ID:: PMC8070027
DOI:: 10.3390/nu13041274
PMID:: 33924457
: Czasopismo naukowe

Full Text Finder

Overweight and obesity in childhood and adolescence represent major public health problems of our century, and account for increased morbidity and mortality in adult life. Irisin and Fibroblast Growth Factor 21 (FGF-21) have been proposed as prognostic and/or diagnostic biomarkers in subjects with obesity and metabolic syndrome, because they increase earlier than other traditional biomarkers. We determined the concentrations of Irisin and FGF-21 in children and adolescents with overweight and obesity before and after one year of a life-style intervention program of diet and physical exercise and explored the impact of body mass index (BMI) reduction on the concentrations of Irisin, FGF-21 and other cardiometabolic risk factors. Three hundred and ten ( n = 310) children and adolescents (mean age ± SD: 10.5 ± 2.9 years) were studied prospectively. Following one year of the life-style intervention program, there was a significant decrease in BMI ( p = 0.001), waist-to-hip ratio ( p = 0.024), waist-to-height ratio ( p = 0.024), and Irisin concentrations ( p = 0.001), and an improvement in cardiometabolic risk factors. There was no alteration in FGF-21 concentrations. These findings indicate that Irisin concentrations decreased significantly as a result of BMI reduction in children and adolescents with overweight and obesity. Further studies are required to investigate the potential role of Irisin as a biomarker for monitoring the response to lifestyle interventions and for predicting the development of cardiometabolic risk factors.

Informacja